Key Takeaway: The USPTO has declined to expand the Federal Circuit’s Allergan safe harbor and kept the “anti-harassment” rationale alive. For biotech and pharma companies with large patent families, careful planning to protect every day of patent term may be needed.
In most industries, a twenty-year patent term is generous. However, it rarely feels that way in the pharmaceutical and biotechnology fields as patent term is consequential and one of the most important economic drivers. Years of discovery, preclinical work, clinical trials, and regulatory review can consume most of the term before a drug ever reaches patients. And by the time a drug reaches the market, the time left to recoup that investment is often a fraction of what the patent promised on paper.
Thus, life-sciences companies guard patent term closely and obviousness-type double patenting (ODP), a relatively quiet corner of patent law, has become one of the most closely watched issues in the field.
Obviousness type double patenting and terminal disclaimers
In 1994, the United States adjusted the patent term from seventeen years from issuance to twenty years from the earliest non-provisional filing date, bringing it in line with most of the world. However, one difference remained: the United States still rejects claims for non-statutory double patenting and allows applicants to overcome those rejections by giving up term.
ODP is a judicially created doctrine that prevents an applicant from obtaining a second patent on an invention that is patentably indistinct from one it already owns, and from unjustly extending its monopoly past the expiration of the first patent. The public policy behind ODP is rooted in the view that upon the expiration of a patent, the public should be free to use the invention and its obvious variants.
The typical mechanism for overcoming an ODP rejection is filing a terminal disclaimer. An applicant agrees that the later patent will expire with the earlier one and that the two will stay under common ownership. Oftentimes that trade is painless, but for a pharmaceutical company, it can mean giving up valuable years of exclusivity.
In re Cellect: PTA becomes vulnerable
In 2023, the Federal Circuit’s In re Cellect decision held that ODP must be assessed using a patent’s expiration date including any PTA.[1] A patent that received PTA could therefore be invalidated by patentably indistinct claims in an earlier-expiring family member. In effect, where a patent has PTA and a terminal disclaimer is filed, the applicant disclaims the PTA term.
For companies with large families and valuable PTA, it meant that the extra term Congress granted to make up for examination delays by the USPTO could be erased by the need to file a terminal disclaimer over the applicant’s own related patents.
Allergan v. MSN Laboratories: a safe harbor for the first-filed, first-issued patent
A year later in Allergan, the same three-judge panel that decided Cellect provided a limited exception to the ruling in Cellect.[2] The Federal Circuit held that “a first-filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date.” As a result, the claims of a first-filed, first-issued patent that is later-expiring due to PTA cannot be invalidated by the claim of a later-filed, later-issued, earlier-expiring child patent having the same priority date.
The Court reasoned that forcing a parent patent to disclaim term over its earlier-expiring child patent would “run afoul of the fundamental purposes of ODP [and] abrogate the benefit Congress intended to bestow on patentees when codifying PTA.” The Court held that the first-filed, first-issued patent in a family sets the maximum period of exclusivity for the claimed subject matter and any patentably indistinct variants.
Patent owners viewed Allergan positively, as it appeared to ensure that PTA grants for first-filed, first-issued patents – which for biotech and pharma companies typically cover the core compound or biologic – cannot be knocked out by later-issuing, earlier-expiring child patents.
Ex parte Baurin: the USPTO declines to expand Allergan and upholds the anti-harassment rationale
In November 2024, the Patent Trial and Appeal Board (Board) issued a decision reversing an Examiner’s rejections for ODP. The patent application at issue was rejected for ODP over several later-expiring reference patents and the Board reversed the rejections, reasoning that granting the application claims when the resulting patent would expire earlier than the reference patents does not extend the patent term or create an unjust monopoly. The Board relied on Allergan and concluded that granting the earlier expiring patent did not trigger ODP under the doctrine’s fundamental purpose.
Director Squires convened an Appeals Review Panel (ARP) and granted sua sponte rehearing to address the Board’s decision, inviting additional briefing from the applicant and amici.
In August 2026, the ARP issued Ex parte Baurin, a precedential decision that clarified what is meant by Allergan’s “first-filed” prong. The ARP held that “first-filed” refers to the actual filing date of the application and therefore does not apply to an application that “does not have the first actual filing [date] in its family.” [3] The ARP rejected the Appellant’s assertion that Allergan’s “first-filed” designation should extend to an application that had an earlier priority date but later actual filing date than an unrelated granted patent cited as the ODP reference. Further, the ARP held that Allergan was not applicable because the application at issue was not the “first-issued” patent – the application was pending while the cited patent had issued. The ARP noted that “[t]he ‘common priority date’ prong refers to patent term filing dates, …” and this prong was not satisfied because the application at issue and cited patent had different patent term filing dates.
Baurin also held that the Board erred in rejecting the anti-harassment rationale as a separate basis for an ODP rejection. The ARP concluded that under current Federal Circuit precedent, an anti-harassment rationale is a valid independent basis for ODP rejections, though this anti-harassment rationale is largely dependent on the possibility of splitting ownership in the future and hypothetical litigation. The concern is that a defendant could be sued separately by different owners of patentably indistinct inventions. Further, this rationale applies even when the challenged patent is the earlier to expire of the two patents.
The ARP, however, signaled discomfort with this outcome, stating that were it not bound by Federal Circuit precedent, it would clarify that the risk of separate ownership and hypothetical harassment should not be a distinct, standalone basis for ODP rejections. It suggested a narrower framework, such as requiring evidence of actual ownership splitting or a two-way obviousness analysis and said it would welcome clarification from the Federal Circuit.
In practice, the universe of potential ODP references available to Examiners remains the same. Based on the anti-harassment rationale for ODP, Examiners can raise ODP rejections for a pending application based on a granted patent even if the patent issuing from the application would expire before the claims of the granted patent. If the application and reference patent are commonly owned, filing of a terminal disclaimer can still overcome such a rejection as it precludes the future severing of ownership and thus prevents harassment of an accused infringer by multiple patent owners. However, common ownership isn’t always present.
For example, the owner of the earlier filed application may enter into a research collaboration with another entity to develop an improvement to their compound, e.g., a formulation, method of use, or delivery device. If the collaboration results in a later-filed, later-expiring patent that is co-owned with the collaborator, filing a terminal disclaimer would not be possible because common ownership is not present. This can be particularly problematic when the improvement is a species of a genus claimed in the earlier-filed application because the applicant cannot argue over the ODP rejection and a terminal disclaimer cannot be filed. Avoiding these potential pitfalls should be a consideration when entering into collaboration agreements for developing improvements.
Although Baurin binds Examiners and the Patent Trial and Appeal Board, it does not bind the Federal Circuit or district courts.
What comes next: In re Ablynx
The Federal Circuit is expected to provide further guidance and consider the question of whether an ODP rejection can rest solely on the risk of harassment when the challenged claims would not create an unjustified extension of patent term in In re Ablynx.[4] A decision is expected in early to mid 2027, and it could reshape ODP practice for companies holding large patent families.
Co-author: Kristine Braddock (Pending California Bar Admission)
Editor: Brenden S. Gingrich, Ph.D.
[1] In re Cellect, 81 F.4th 1216 (Fed. Cir. 2023).
[2] Allergan USA, Inc. v. MSN Laboratories Private Ltd., 111 F.4th 1358 (Fed. Cir. 2024).
[3] Ex parte Baurin, Appeal 2024-002920, Application No. 17/135,529 (USPTO ARP Aug. 6, 2026).
[4] In re Ablynx N.V., No. 26-1333 (arising from Ex parte Baumeister).